Generating Intellectual Property Through Solid Form Landscape and Formulation Development

In drug discovery and development, intellectual property (IP) is often as critical as the science itself. Strong IP protection helps innovators secure investment, differentiate their therapies from competitors, and create the commercial foundations needed to bring new medicines to patients. For companies developing assets in crowded or well-established therapeutic areas, building a robust and defensible IP portfolio can be the difference between a promising molecule and a commercially viable product.

At Sygnature Discovery, we understand that generating value for our clients extends beyond delivering high-quality scientific data. By combining expertise in solid-state chemistry, formulation development, and pharmaceutical sciences with a strategic understanding of intellectual property, we help clients identify opportunities to strengthen protection around their assets throughout development. Whether through solid form characterization, salt screening, or formulation innovation, our teams work to generate the scientific evidence that can support patent filings, reduce competitive risk, and maximize the long-term value of a program.

This case study demonstrates how an integrated solid form, formulation, and IP strategy helped a biotechnology client transform a well-known molecule into a more defensible development asset, strengthening its intellectual property position while advancing it toward late-stage clinical development.

The Challenge of Developing a Well-Established Molecule

A small biotechnology company was developing a therapeutic candidate based on a molecule that was already well established in literature. While the molecule showed promise as a new therapy, its extensive prior history presented a significant intellectual property challenge. The client needed a strategy that would support long-term differentiation, strengthen patent protection, and maximize the commercial value of the program.

Developing well-characterized molecules can offer significant advantages, including existing knowledge of their chemistry, safety profile, and biological activity. This can reduce development risk and accelerate progress compared with discovering an entirely new therapeutic candidate. However, these benefits are often accompanied by intellectual property challenges, making a robust IP strategy essential for long-term commercial success.

In addition to this, the compound of interest exhibited exceptionally high solubility, which created challenges for formulation. The customer wanted to slow the rate of dissolution to reduce peak plasma concentrations (Cmax) and extend the time to maximum concentration (Tmax), with the goal of improving tolerability in the clinic.

Using Our Expertise to Protect Your Science

The customer required more than technical development support. They needed a partner capable of integrating solid-state chemistry, formulation expertise, and intellectual property considerations into a single development strategy.

Sygnature Discovery works closely with customers to ensure that intellectual property considerations inform key development decisions from the earliest appropriate stage. This collaborative approach enables opportunities for patent generation and portfolio expansion to be identified alongside our discovery programs, maximizing opportunities to generate and protect value.

Building an IP Strategy Through Solid Form and Formulation Development

In this case, Sygnature Discovery implemented a comprehensive solid form and formulation development strategy.

First, a full polymorph screening study was conducted on the client’s selected API salt form. Multiple crystal forms were identified and characterized. While the form already being manufactured under Good Manufacturing Practice (GMP) conditions remained the most appropriate candidate for development, the study generated valuable data on alternative forms that could be used to strengthen the overall IP position.

The team then performed a comprehensive salt screening program. Although the client did not anticipate changing the selected salt form, identifying and characterizing alternative salts created additional patent opportunities. Multiple crystalline forms were discovered, and complete XRPD and thermal characterization data packages were generated to support IP filings.

In parallel, formulation scientists addressed the challenges associated with the compound’s unusually high solubility. Through careful excipient selection and extensive in vitro dissolution testing, Sygnature developed a formulation capable of extending the dissolution profile while maintaining suitability for further development (Figure 1).

Reducing Risk and Expanding IP Protection

The polymorph and salt screening studies provided a detailed understanding of the compound’s solid-state landscape. This work confirmed that the existing GMP-manufactured form remained the preferred development candidate while simultaneously identifying alternative forms and salts that could support additional patent filings.

The formulation program successfully addressed a challenging pharmaceutical property. By extending the dissolution profile, the team generated a more suitable dosage form aligned with the desired clinical performance objectives.

The integrated development strategy reduced both scientific and intellectual property risk. The client progressed with confidence in their chosen solid form while expanding protection around the broader molecular space through additional patentable forms and salts.

The formulation knowledge generated during development was successfully transferred to the client’s GMP drug product manufacturer, supporting production of Phase III clinical trial material. Importantly, the transfer was completed with future commercial manufacturing considerations in mind.

Creating Long-Term Value Through IP Generation

By combining solid-state characterization, formulation optimization, and intellectual property strategy, Sygnature Discovery helped transform a well-known molecule into a more defensible development asset. The resulting IP portfolio helped establish a protective IP fence around the molecule, creating additional barriers to competitive entry while supporting the client’s long-term commercialization strategy.

The optimized formulation and successful technology transfer positioned the program for late-stage clinical development and potential commercial manufacture, helping the client increase the value and competitive strength of their therapeutic candidate.

Key Takeaways

• Comprehensive polymorph screening generated data that supported protection of the solid-form landscape.
• Extensive salt screening identified multiple crystalline forms suitable for intellectual property filings.
• Integrated scientific and IP expertise enabled opportunities for patent generation to be identified early in development.
• Formulation development successfully extended the dissolution profile of an unusually soluble compound.
• Technology transfer supported manufacture of Phase III clinical material and future commercialization objectives.
• The combined strategy strengthened both the scientific and commercial position of the program.